Search

John P Burnier

from Lanai City, HI
Age ~72
Get Report
Also known as:
John So Burnier
Related to:
Tammy J Harrison, 36Lance K Harrison, 55Shirlene Tabao, 49Martha Esparza
Connected to:
Claudio Burnier, 64Dewayne D Burnight, 63Michelle A Burnight, 49Barry O Burnikel, 67Keith M Burnikell, 64Michael S Burnim, 38Aaron J Burningham, 42Christian L Burningham, 44Jamie A Burningham, 57Kelly R Burningham, 76

John Burnier Phones & Addresses

  • Lanai City, HI
  • 211 Sterling Ave, Pacifica, CA 94044 (650) 359-2093
  • Occidental, CA
  • Bella Vista, CA
  • San Diego, CA
  • Honolulu, HI
  • Poway, CA
  • 211 Sterling Ave, Pacifica, CA 94044 (650) 303-8958

Work

Company: Sarcode corporation Mar 2006 to Oct 2010 Position: President

Education

Degree: Associate degree or higher

Emails

a***[email protected]

Industries

Biotechnology

Resumes

Resumes

John Burnier Photo 1

President

View page
Location:
San Francisco, CA
Industry:
Biotechnology
Work:
Sarcode Corporation Mar 2006 - Oct 2010
President
Jb Consulting Mar 2006 - Oct 2010
President
Genentech 1983 - 2003
Director, Bioorganic Chemistry

Business Records

Name / Title
Company / Classification
Phones & Addresses
John Burnier
President
PEDRO POINT IMPROVEMENT ASSOCIATION, INCORPORATION
PO Box 951, Pacifica, CA 94044
1227 Danmann Ave, Sharp Park, CA 94044

Publications

Us Patents

Receptor Specific Atrial Natriuretic Peptides

View page
US Patent:
6525022, Feb 25, 2003
Filed:
Sep 16, 1998
Appl. No.:
09/154390
Inventors:
David G. Lowe - Brisbane CA
Brian C. Cunningham - Piedmont CA
David Oare - Belmont CA
Robert S. McDowell - San Francisco CA
John P. Burnier - Pacifica CA
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 3812
US Classification:
514 11, 514 12, 530317, 530324, 530327, 435 691
Abstract:
Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.

Low Molecular Weight Peptidomimetic Growth Hormone Secretagogues

View page
US Patent:
7094869, Aug 22, 2006
Filed:
Aug 19, 2002
Appl. No.:
10/224640
Inventors:
Todd C. Somers - Foster City CA, US
Kathleen A. Elias - San Francisco CA, US
Ross G. Clark - Pacifica CA, US
Robert S. McDowell - San Francisco CA, US
Mark S. Stanley - Pacifica CA, US
John P. Burnier - Pacifica CA, US
Thomas E. Rawson - Mountain View CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
C07K 5/08
US Classification:
530331, 530330, 517 17, 517 18
Abstract:
The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound of this invention is provided below.

Drug Design For Tubulin Inhibitors, Compositions, And Methods Of Treatment Thereof

View page
US Patent:
7538252, May 26, 2009
Filed:
Sep 5, 2007
Appl. No.:
11/850620
Inventors:
Valeria Ossovskaya - San Francisco CA, US
John Burnier - Pacifica CA, US
Barry Sherman - Hillsborough CA, US
Max Totrov - San Diego CA, US
Assignee:
BiPar Sciences, Inc. - Brisbane CA
International Classification:
C07C 213/00
C07C 49/00
C07C 41/00
US Classification:
564430, 568335, 568336, 568635
Abstract:
The present invention relates to a computer-assisted method of a designing of a tubulin inhibitor comprising: a) determining an interaction between a tubulin protein and a chemical known to bind the tubulin protein by evaluating a binding of the tubulin protein to the chemical known to bind the tubulin protein; b) based on the interaction, designing a candidate tubulin inhibitor; c) determining an interaction between the tubulin protein and the candidate tubulin inhibitor by evaluating a binding of the tubulin protein to the candidate tubulin inhibitor; and d) concluding that the candidate tubulin inhibitor inhibits the tubulin protein wherein the conclusion is based on the interaction of step c). The invention also provides compositions and methods of treatment of diseases with the candidate tubulin inhibitors.

Crystalline Pharmaceutical And Methods Of Preparation And Use Thereof

View page
US Patent:
8080562, Dec 20, 2011
Filed:
Apr 15, 2009
Appl. No.:
12/386361
Inventors:
John Burnier - Pacifica CA, US
Thomas Gadek - Oakland CA, US
Frederic Naud - Binningen, CH
Assignee:
Sarcode Bioscience Inc. - Brisbane CA
International Classification:
A61K 31/47
C07D 217/02
US Classification:
514307, 546146
Abstract:
Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.

Treatment Of Cancer

View page
US Patent:
8143447, Mar 27, 2012
Filed:
Sep 5, 2007
Appl. No.:
11/850626
Inventors:
Jerome Moore - Issaquah WA, US
Bruce Keyt - Hillsborough CA, US
John Burnier - Pacifica CA, US
Barry M. Sherman - Hillsborough CA, US
Max Totrov - San Diego CA, US
Valeria S. Ossovskaya - San Francisco CA, US
Assignee:
BiPar Sciences, Inc. - South San Francisco CA
International Classification:
C07C 233/65
C07C 323/42
C07C 323/62
US Classification:
564162, 562431
Abstract:
The present invention provides compositions of matter, kits and methods for their use in the treatment of cancer. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase, as well as providing formulations and modes of administering such compositions.

Compositions And Methods For Treatment Of Eye Disorders

View page
US Patent:
8168655, May 1, 2012
Filed:
May 17, 2006
Appl. No.:
11/436906
Inventors:
Thomas Gadek - Oakland CA, US
John Burnier - Pacifica CA, US
Assignee:
SARcode Bioscience Inc. - Brisbane CA
International Classification:
A61K 31/47
US Classification:
514307, 514912
Abstract:
The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.

Crystalline Pharmaceutical And Methods Of Preparation And Use Thereof

View page
US Patent:
8367701, Feb 5, 2013
Filed:
Nov 4, 2011
Appl. No.:
13/289172
Inventors:
John Burnier - Pacifica CA, US
Thomas Gadek - Oakland CA, US
Frederic Naud - Binningen, CH
Assignee:
SARcode Bioscience Inc. - Brisbane CA
International Classification:
A61K 31/47
C07D 217/00
US Classification:
514307, 546146
Abstract:
Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.

Crystalline Pharmaceutical And Methods Of Preparation And Use Thereof

View page
US Patent:
8378105, Feb 19, 2013
Filed:
Oct 21, 2010
Appl. No.:
12/909241
Inventors:
John Burnier - Pacifica CA, US
Assignee:
SARcode Bioscience Inc. - Brisbane CA
International Classification:
C07D 401/02
US Classification:
546146
Abstract:
Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
Control profile
John P Burnier from Lanai City, HI, age ~72 Get Report